Co-Diagnostics, Inc. filings document a molecular diagnostics company’s operating results, material events, governance actions, and capital-structure disclosures. Recent 8-K filings cover financial results, Regulation FD disclosures, non-GAAP presentation references, Nasdaq listing-rule matters, and other corporate events tied to the company’s common stock.
Proxy and material-event filings also describe shareholder voting matters, including authorization for a reverse stock split, along with governance procedures and security-structure changes. The filing record links the company’s Co-Dx PCR platform, clinical and regulatory disclosures, commercialization activities, and public-company reporting obligations with risk, liquidity, listing, and ownership-related disclosure categories.
Co-Diagnostics, Inc. (CODX) shareholders approved an amendment to the 2025 Equity Incentive Plan on November 13, 2026, making it effective that day. It adds 2,000,000 shares to the plan’s authorized issuance; the maximum for awards is 2,223,333 shares, plus shares that become available from canceled or forfeited 2015 plan awards. Incentive stock options have the same 2,223,333-share maximum. Other plan terms were not materially changed.
Shareholders authorized one or more reverse splits at ratios no less than 1-for-2, with cumulative effect capped at 1-for-750; the board may set ratios and timing within 12 months. They approved potential exercise of warrants for 3,404,724 shares at $1.56 each and issuance of shares upon conversion of secured convertible notes. They also approved a one-third quorum threshold, adopted a non-binding executive-compensation resolution, ratified Tanner LLC as independent registered public accounting firm for the year ending December 31, 2026, and elected Dwight Egan, Eugene Durenard, Richard Serbin, James Nelson and Edward Murphy as directors for one-year terms.
Co-Diagnostics, Inc. (CODX) reported third-quarter 2026 revenue of $282,881, compared with $145,380 a year earlier, while its net loss was $6,306,408 versus $5,886,823. Cost of revenue exceeded product revenue, resulting in a $20,463 gross loss, compared with $119,095 gross profit in the 2025 quarter. For the first nine months, revenue was $594,966 versus $358,567, and net loss was $21,730,232 versus $21,150,211.
Cash and cash equivalents were $714,803 as of September 30, 2026, compared with $11,884,607 as of December 31, 2025. Operating activities used $20,683,301 during the nine months; financing activities provided $9,838,796, including $5,177,214 from a private placement and warrant exercises and $4,661,582 from an at-the-market offering, net of offering costs.
Management concluded that substantial doubt exists about the Company’s ability to continue as a going concern for 12 months from the date the statements are issued. It said continued operations depend on additional capital and future profitability. Plans include equity or debt financing, grants and operational efficiencies; management said some mitigating plans are outside its control and there can be no assurance that sufficient capital can be raised on acceptable terms.
Co-Diagnostics, Inc. (CODX) reported third-quarter 2026 revenue of $282,881, compared with $145,380 a year earlier, while its net loss was $6,306,408 versus $5,886,823. Operating expenses were $6,248,887, down 12% year over year, but cost of revenue rose to $303,344 from $26,285, producing a gross loss of $20,463 compared with gross profit of $119,095.
Cash and cash equivalents were $714,803 on September 30, 2026, versus $11,884,607 on December 31, 2025. The company said two submissions were under review: its tuberculosis test submission to India’s CDSCO after completion of a clinical performance study, and an August FDA 510(k) submission for Flu A/B & RSV. It launched cloud and mobile infrastructure in India, began evaluating blood-based testing with ReadyGo, and completed Vector Smart’s first international deployment. The Co-Dx PCR platform and associated tests remain subject to regulatory review and are not yet available for sale.
Co-Diagnostics, Inc.'s registration statement covers up to 39,594,495 common shares for resale by J.J. Astor & Co. after effectiveness. Co-Diagnostics receives no proceeds from these resales; Astor receives the net proceeds. The shares include stock issued or issuable on conversion of the Notes, 600,000 commitment shares and applicable make-whole shares. The registered amount equals 200% of the sum of maximum conversion shares at the floor price, commitment shares and applicable make-whole shares, assuming the additional loan is fully funded.
Under an October 9, 2026 loan agreement, Astor initially funded $2.1 million; Co-Diagnostics issued a senior secured convertible note with $2.835 million original principal and received approximately $2.016 million net before other transaction expenses. Subject to the agreement's conditions, the company may borrow another $1.0 million beginning 60 days after the agreement date and issue a $1.35 million original-principal note. The Notes are repaid in 30 weekly installments, secured by liens on substantially all company and subsidiary assets, and require a $250,000 minimum cash balance while outstanding. Co-Diagnostics had 9,491,892 shares outstanding as of October 31, 2026.
Co-Diagnostics, Inc. is asking shareholders to vote at a special meeting on November 13, 2026, on nine proposals, including five director nominees, an equity-plan amendment, advisory executive compensation, auditor ratification, a quorum amendment, warrant and convertible-note share issuance, a reverse split authorization and adjournment. A court order sets the quorum for each applicable voting group at one-third of the votes entitled to be cast.
The proposed equity-plan amendment would add 2,000,000 shares to the existing 263,376-share authorization, for 2,263,376 shares if approved. The requested increase represents approximately 22.7% of the 8,822,648 common shares outstanding as of October 22, 2026. Other proposals seek approval of the potential exercise of 3,404,724 warrants at $1.56 per share and the issuance of shares upon conversion of secured convertible notes. Shareholders are also asked to authorize one or more reverse splits at a ratio of not less than 1-for-2, with a cumulative effect not to exceed 1-for-750; the board would determine the ratio and timing within twelve months after the meeting.
Co-Diagnostics, Inc. is seeking shareholder votes on nine proposals at a court-ordered special meeting. They include electing five directors; increasing the 2025 Equity Incentive Plan share reserve; advisory approval of executive compensation; auditor ratification; approvals involving warrant exercise and secured-note conversion shares; a quorum amendment; reverse-split authority; and adjournment.
The plan proposal requests 2,000,000 additional shares, which would increase the plan authorization from 223,333 to 2,223,333 shares if approved. The requested increase represents approximately 24.7% of common stock outstanding as of the Record Date. A separate proposal seeks approval of the potential exercise of new warrants to purchase 3,404,724 shares at $1.56 per share. The proxy also lists approximately 2,600,917 shares underlying the outstanding convertible note as of the Record Date.
The proposed reverse-split authority would permit one or more reverse splits at ratios of not less than 1-for-2, with a cumulative effect not to exceed 1-for-750. The Board would determine the ratios, number and timing within 12 months following the meeting, without further shareholder approval. A court order sets quorum at one-third (33 1/3%) of votes entitled to be cast by the applicable voting group for this meeting and any properly reconvened session. The Board unanimously recommends “FOR” all proposals.
Co-Diagnostics, Inc. (CODX) was unable to conduct business at its October 14, 2026 annual meeting because a quorum was not present or represented. The company also lacked a quorum at its September 3 meeting and at reconvenings on September 24 and September 30. It decided not to adjourn again and currently intends to seek stockholder approval of the proposals at a special meeting on a future date. If it proceeds, the company will provide meeting details and additional information in proxy materials.
Co-Diagnostics, Inc. (CODX) disclosed a senior secured convertible loan with J.J. Astor & Co. for up to $3.1 million; $2.1 million was funded initially. The initial note has $2.835 million original principal at a 1.35-times factor rate, with approximately $2.016 million in initial net cash proceeds before other transaction expenses. Beginning 60 days after the Loan Agreement date, the company may elect an additional $1.0 million, subject to the agreement’s conditions.
The notes are payable in 30 weekly installments, secured by a senior-priority lien on substantially all company and existing subsidiary assets, and require a $250,000 minimum cash balance while outstanding. The company issued 600,000 commitment shares. ATM proceeds go to an account subject to lender control: the first $1.0 million is payable to the lender; later allocations are 80% to the notes and 20% to the company until that week’s installments are met, then 25% and 75% for the rest of the week. After default, 80% goes to the notes and 20% to the company. Conversion pricing is tied to the lowest volume-weighted average price during the preceding 10 trading days and Nasdaq minimum price, subject to floors and issuance limits.
Co-Diagnostics, Inc. entered a senior secured convertible loan agreement with J.J. Astor & Co. for up to $3.1 million in aggregate principal funding. At closing, the lender funded $2.1 million and the company issued an initial note with $2.835 million original principal, reflecting a 1.35-times factor rate; initial net cash proceeds were approximately $2.016 million before other transaction expenses. Beginning 60 days after the agreement date, subject to its conditions, the company may elect an additional $1.0 million loan for a note with $1.35 million original principal.
The notes are secured by a senior-priority lien on substantially all company and existing-subsidiary assets, require a $250,000 minimum cash balance and are payable in 30 weekly installments. The conversion price is the greater of 90% of the lowest VWAP in the prior 10 trading days and the Nasdaq minimum price, subject to a floor; conversions also face a 9.99% ownership cap. Upon default, principal is increased to 120% of then-outstanding principal and bears 19% annual interest, compounded daily. The ATM waterfall sends its first $1.0 million of net proceeds to the lender; thereafter, 80% is applied to the notes and 20% released to the company until the applicable week's installments are met, then 25% and 75%, respectively, for that week's remainder.
Co-Diagnostics, Inc. adjourned its annual meeting to October 14, 2026, at 9:30 a.m. Mountain Time after failing to achieve a quorum on September 30, 2026. The meeting also lacked a quorum on September 3 and at its September 24 adjournment. Stockholders will vote at the reconvened meeting in the manner described in the definitive proxy statement. Previously submitted valid proxies remain effective unless properly changed or revoked before votes are taken.